Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015

Date: September 9, 2015
Pages: 60
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0AD8B932E5EN
Leaflet:

Download PDF Leaflet

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acquired (Autoimmune) Hemolytic Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acquired (Autoimmune) Hemolytic Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acquired (Autoimmune) Hemolytic Anemia Overview
Therapeutics Development
Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Overview
Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics under Development by Companies
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Acquired (Autoimmune) Hemolytic Anemia - Products under Development by Companies
Acquired (Autoimmune) Hemolytic Anemia - Companies Involved in Therapeutics Development
Agios Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Hansa Medical AB
Shire Plc
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AG-348 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endoglycosidase of Streptococcus pyogenes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TNT-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TNT-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acquired (Autoimmune) Hemolytic Anemia - Recent Pipeline Updates
Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects
Acquired (Autoimmune) Hemolytic Anemia - Product Development Milestones
Featured News & Press Releases
Jun 12, 2015: Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase Deficiency
May 21, 2015: Agios to Present Clinical and Preclinical Data On AG-348 at the 20th Congress of the European Hematology Association
Mar 24, 2015: Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
Dec 08, 2014: Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
Nov 06, 2014: Agios Pharmaceuticals To Present Phase 1 Data On AG-348 At The 2014 American Society Of Hematology Annual Meeting
Oct 06, 2014: Agios Pharmaceuticals to Provides Update on AG-348 Webcast R&D Day on October 15, 2014
Jun 09, 2014: Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia
Apr 17, 2014: Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Apr 14, 2014: True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo Efficacy of a C1s Antibody in Cold Agglutinin Disease Patient Samples
Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2015
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Hansa Medical AB, H2 2015
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Shire Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Recent Pipeline Updates, H2 2015
Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Agios Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Hansa Medical AB
Shire Plc
Skip to top


Ask Your Question

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: